Diquafosol tetrasodium. Inspire/Allergan/Santen.
Inspire, in collaboration with Allergan and Santen, is developing an eye-drop formulation of diquafosol tetrasodium (INS-365), a second-generation uridine nucleotide analog P2Y, receptor agonist for the potential treatment of dry eye disease. In June 2003, Inspire submitted an NDA for the treatment of dry eye, and in July 2003 the FDA granted the NDA Priority Review status. FDA action is expected in December 2003, and in January 2003 launch was expected in the first half of 2004.
Fischbarg
Jorge
J
Department of Physiology and Cellular Biophysics, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA. jf20@columbia.edu
D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D015352:Dry Eye Syndromes / Q000188:drug therapy*; D006207:Half-Life; D006801:Humans; D009883:Ophthalmic Solutions / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D011122:Polyphosphates / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D016896:Treatment Outcome; D014500:Uracil Nucleotides / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use
D009883:Ophthalmic Solutions; D011122:Polyphosphates; D014500:Uracil Nucleotides; C403315:diquafosol